Eric MD - EQRx Chief Exec
| EQRXDelisted Stock | USD 1.83 0.13 6.63% |
Insider
Eric MD is Chief Exec of EQRx Inc
| Age | 58 |
| Phone | 617 315 2255 |
| Web | https://www.eqrx.com |
EQRx Management Efficiency
The company has return on total asset (ROA) of (0.1379) % which means that it has lost $0.1379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2025) %, meaning that it created substantial loss on money invested by shareholders. EQRx's management efficiency ratios could be used to measure how well EQRx manages its routine affairs as well as how well it operates its assets and liabilities.EQRx Inc currently holds 3.83 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. EQRx Inc has a current ratio of 28.18, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about EQRx's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Vijay Sabesan | Kymera Therapeutics | 52 | |
| Kevan Shokat | Revolution Medicines | N/A | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Elaine Caughey | Kymera Therapeutics | N/A | |
| MA MBA | Relay Therapeutics | 48 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Nellie Dillery | Lyell Immunopharma | N/A | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Nello MD | Kymera Therapeutics | 45 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Melissa Brody | Kymera Therapeutics | N/A | |
| Bruce CFA | Kymera Therapeutics | N/A | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Stephen Hill | Lyell Immunopharma | 54 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Michael Fischbach | Revolution Medicines | 43 | |
| Mark Murcko | Relay Therapeutics | 64 | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 |
EQRx Inc Leadership Team
Elected by the shareholders, the EQRx's board of directors comprises two types of representatives: EQRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EQRx. The board's role is to monitor EQRx's management team and ensure that shareholders' interests are well served. EQRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EQRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Hoey, Chief Operations | ||
| Robert LLB, CoFounder Advisor | ||
| Alexis AM, Founder Directors | ||
| MAPP MD, CoFounder Advisor | ||
| Jamilu Rubin, Chief Officer | ||
| Sir CBE, CoFounder Advisor | ||
| Rona Anhalt, Chief Officer | ||
| Eric MD, Chief Exec | ||
| Melanie Nallicheri, CEO Director | ||
| Dina JD, Gen Sec |
EQRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EQRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (75.06 M) | |||
| Shares Outstanding | 487.7 M | |||
| Shares Owned By Insiders | 11.13 % | |||
| Shares Owned By Institutions | 68.24 % | |||
| Number Of Shares Shorted | 11.3 M | |||
| Price To Book | 1.00 X | |||
| EBITDA | (517.58 M) | |||
| Net Income | (169.09 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in EQRx Stock
If you are still planning to invest in EQRx Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EQRx's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |